MedPath

Prevention of COPD exacerbation by normalizing serum vitamin D3 level.

Phase 4
Conditions
Chronic Obstructive Pulmonary Disease.
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
Registration Number
IRCT2016022826816N1
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
66
Inclusion Criteria

Inclusion criterial: All COPD patients including those with emphysema and chronic bronchitis with serum vitamin D-25 level less than 75 nmol/L.
Exclusion criterial: 1. patients younger than 40 yrs; 2. patients with FEV1/FVC < 70%; 3. patients that after inhalation of 400 microgra salbutamol have FEV1/FVC > 70%; 4. patients with history of consumtion of less than 15 pack year cigarettes; 5. patient with asthma or history of asthma; 6. patients with serum level of vitamine D > 75 mnol/L; 7. patients with diabetes, renal failure, history of MI, bronchiectasia, sarcoidosis, hypoparathyroidism, nephrolithiasis, active TB, liver failure, malignancy with remission less than 3 years age; 8. patients under treatment with carbamazepine, cardiac glycosides, phenobarbital, phenytoin, perimidon; 9. patients with serum calcium level above 2.65 mmol/L or serum creatinine level above 125 micromol/L; 10. patients unable to cooperate with spirometery; 11. patient who need to receive more than 12 hrs per day oxygen.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurance of an exacerbation of COPD. Timepoint: Monthly. Method of measurement: clinical and paraclinical observations.
Secondary Outcome Measures
NameTimeMethod
Functional class of the patients. Timepoint: End of the study. Method of measurement: clinical observation and interview.
© Copyright 2025. All Rights Reserved by MedPath